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LETTERS TO THE EDITOR
Congenital Erythropoietic Porphyria: a Novel Homozygous
Mutation in a Japanese Patient
To the Editor:
Congenital erythropoietic porphyria (CEP; MIM#263700) is an
extremely rare disorder inherited as an autosomal recessive trait.
The cause of this disease is the de®cient activity of uroporphyrino-
gen III synthase (UROIIIS). CEP is characterized by severe
cutaneous photosensitivity, chronic hemolysis, and massive por-
phyrinuria resulting from the accumulation in the bone marrow,
peripheral blood, and other organs of large amounts of predomi-
nantly type I porphyrins, which are not substrates for heme
synthesis. Since a cloning of UROIIIS gene (UROS; Genebank
NM000375), efforts have been made to clarify underlying
mutations that cause CEP (Fontanellas et al, 1996). Here we report
a novel mutation in a Japanese patient with CEP.
A 54-y-old male, whose parents are consanguineous, presented
with skin vesicles, ulcer with scaring, and sclerotic changes of the
eyes. Biochemical examination revealed mild liver dysfunction.
Analysis of urinary porphyrins revealed an increased excretion of
uroporphyrin and coproporphyrin. UROIIIS enzymatic activity in
whole blood was very low (less than 2% compared with the normal
control).
Genomic DNA analysis using 5¢ and 3¢ primers of each of the
nine exons of UROIIIS revealed that he had a novel missense
mutation: a C to T transition of nucleotide 386 that predicted a
isoleucine to threonine substitution at residue 129 (I129T) at the
homozygous state (data not shown). Furthermore, the correspond-
ing mutated protein was expressed in Escherichia coli and no residual
activity was observed (Table I).
To date, over 20 mutations have been reported on UROS,
including C73R, the most frequent mutation in Western
countries. Interestingly, including this case, C73R has not been
reported in Japanese cases of CEP (Takamura et al, 1996),
which suggests the possibility of a difference in genetic pro®le
of CEP cases between Western countries and Japan. Genotype-
phenotype correlation of CEP cases in Japan has not been
clari®ed because of the rarity of this disease. Further analysis
will be necessary for its clari®cation.
Screening of CEP families with the mutations at the DNA level
would lead to genetic counseling and prenatal diagnosis as similar to
other congenital genetic disorders. Because HLA-identical allo-
genic bone-marrow transplantation has already been proposed to
severely affected patients (Thomas et al, 1996), establishment of
screenings for the genetic diagnosis of CEP could potentially lead to
the use of somatic gene therapy for CEP-treating patients in the
future (Moreau-Gaudry et al, 1996).
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Table I. Functional expression assay with the mutant vectora
Plasmid Speci®c activity
(U per mg protein)
Number of
assays
Residual
activity
Mean SD
pKK 0.28 0.34 4 <2
pKK-wt 151 30 6 100
pKK-I129T (I129T) 0.30 0.17 5 <2
aMutant UROS-cDNA was constructed with Ex-Site PCR-Based Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA) in the bacterial expression vector
pKK223-3 (Pharmacia Biotech, Sweden), according to the manufacturer's
instruction. The resultant E. coli cells were transformed with pKK-mutant-
UROIIIS or pKK-wt-UROIIIS and grew at 37°C. The protein expression was
induced by growing the cells in the presence of IPTG. UROIIIS speci®c activity
(SA) is expressed as the relative amount of UROIIIS (nmoles) formed in 1 h per
mg of protein. Residual activity (as a percentage of the normal UROIIIS speci®c
activity) was determined by dividing 1003 [SA±SA(pKK)] by [SA(pKKUROIIIS)
± SA(pKK)] where SA (pKK) and SA (pKKUROIIIS) are the speci®c activities of
the lysate (empty plasmid) and of the normal UROIIIS protein respectively.
0022-202X/00/$15.00 ´ Copyright # 2000 by The Society for Investigative Dermatology, Inc.
1156
